An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease.
Phase of Trial: Phase II
Latest Information Update: 23 May 2016
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Mar 2012 Additional lead trial investigator(Yukihiro Kumamoto) identified as reported by ClinicalTrials.gov.
- 29 Nov 2011 New trial record